Cycle Length and Continuous Use Clinical trials have safely used AOD-9604 for durations ranging from single doses to 24 weeks of continuous daily administration
The net result of AOD9604 action is preferential reduction of adipose tissue mass, particularly visceral and subcutaneous fat depots, without the hyperglycemic, insulin-desensitizing, or growth-promoting effects of full-length growth hormone
Theoretically, this supports the production of lipoproteins that transport fats from the liver, potentially reducing hepatic fat accumulation
Typical injection dosages can range from: 1,000 mcg (1 milligram) given weekly, monthly, or on a less frequent schedule depending on the severity of the deficiency and the individuals response
Review of regenerative and gene-expression research involving GHK-Cu